n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Disease Models, Animal in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (8.70) | 18.2507 |
2000's | 9 (39.13) | 29.6817 |
2010's | 9 (39.13) | 24.3611 |
2020's | 3 (13.04) | 2.80 |
Authors | Studies |
---|---|
Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Bai, H; Gao, L; Jiao, G; Li, T; Liu, L; Ma, T; Song, X; Wang, X; Zhang, Z | 1 |
Atar, E; Bar-Yehuda, S; Barer, F; Castel, D; Cohen, S; Del Valle, L; Fishman, P; Ochaion, A; Patoka, R; Perez-Liz, G; Piña-Oviedo, S; Rath-Wolfson, L; Zozulya, G | 1 |
Arich, A; Bar-Yehuda, S; Dreznick, Z; Fishman, P; Madi, L; Ohana, G; Rath-Wolfson, L; Silberman, D; Slosman, G | 1 |
Bar-Yehuda, S; Fishman, P; Gery, S; Madi, L; Shkapenuk, M; Silberman, D | 1 |
Assumpção, JAF; Caumo, W; Cioato, SG; de Souza, A; Lopes, BC; Medeiros, HR; Medeiros, LF; Roesler, R; Torres, ILS | 1 |
Celinski, K; Czechowska, G; Korolczuk, A; Madro, A; Prozorow-Krol, B; Slomka, M | 1 |
Cuzzocrea, S; Doyle, T; Esposito, E; Jacobson, KA; Janes, K; Salvemini, D; Tosh, DK | 1 |
French, BA; Linden, J; Marshall, M; Tian, Y; Yang, Z | 1 |
Castonguay, A; Chen, Z; Cottet, M; De Koninck, Y; Doyle, T; Egan, TM; Ford, A; Jacobson, KA; Little, JW; Salvemini, D; Symons-Liguori, AM; Tosh, DK; Vanderah, TW | 1 |
Ambrósio, AF; Cordeiro, MF; Elvas, F; Galvao, J; Martins, T; Santiago, AR | 1 |
Feng, C; Yan, H; Zhang, E; Zhao, X | 1 |
Gazoni, LM; Kron, IL; Laubach, VE; Linden, J; Unger, EB; Walters, DM | 1 |
Auchampach, JA; Ge, ZD; Gross, GJ; Moore, J; Wan, TC | 1 |
Haskó, G; Mabley, J; Marton, A; Pacher, P; Salzman, A; Soriano, F; Szabó, C; Wallace, R | 1 |
Fang, G; Linden, J; Scheld, WM; Sullivan, GW | 1 |
Galun, E; Matot, I; Rivo, J; Zeira, E | 1 |
Auer, H; Bozarov, A; Cardounel, AJ; Christofi, FL; Cooke, H; Grants, I; Guzman, J; Hassanain, HH; Javed, A; Javed, N; Palatini, J; Suntres, Z; Wunderlich, JE; Yu, JG | 1 |
Buchholz, RA; Hill, RJ; Kennedy, SP; Knight, DR; Magee, W; Masamune, H; Tracey, WR | 1 |
Egnaczyk, G; Haskó, G; Salzman, AL; Scott, GS; Shanley, TP; Szabó, C; Virág, L | 1 |
23 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Disease Models, Animal
Article | Year |
---|---|
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
CF101 alleviates OA progression and inhibits the inflammatory process via the AMP/ATP/AMPK/mTOR axis.
Topics: Adenosine; Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Cartilage, Articular; Chondrocytes; Collagen Type II; Disease Models, Animal; Inflammation; Osteoarthritis; Rats; TOR Serine-Threonine Kinases | 2022 |
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Apoptosis; Cartilage, Articular; Disease Models, Animal; Inflammation; Iodoacetates; Male; NF-kappa B; Osteoarthritis; Rats; Rats, Wistar; Signal Transduction | 2009 |
Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.
Topics: Adenosine; Administration, Oral; Animals; Biological Availability; Carcinoma; Cell Division; Colonic Neoplasms; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Purinergic P1 Receptor Agonists; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Antinociceptive and neurochemical effects of a single dose of IB-MECA in chronic pain rat models.
Topics: Adenosine; Analgesics; Animals; Chronic Pain; Disease Models, Animal; Inflammation; Male; Neuralgia; Rats; Rats, Wistar | 2020 |
The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Edema; Injections, Intraperitoneal; Lipase; Male; Necrosis; Pancreas; Pancreatic alpha-Amylases; Pancreatitis, Acute Necrotizing; Rats; Rats, Wistar; Receptor, Adenosine A3; Taurocholic Acid; Time Factors | 2013 |
A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Antineoplastic Agents, Phytogenic; Cytokines; Disease Models, Animal; Excitatory Amino Acid Transporter 2; Hyperalgesia; Male; NADP; Neuralgia; Neuroglia; NF-kappa B; Oxidation-Reduction; Paclitaxel; Rats; Rats, Sprague-Dawley; Signal Transduction; Spinal Cord; Tumor Necrosis Factor-alpha | 2014 |
The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors.
Topics: Adenosine; Animals; Disease Models, Animal; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Adenosine A2A; Receptor, Adenosine A3 | 2015 |
Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Hyperalgesia; K Cl- Cotransporters; Male; Mice; Pain Threshold; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Sciatica; Signal Transduction; Spinal Nerve Roots; Symporters; Thiazoles; Thioglycolates | 2015 |
Adenosine A3 receptor activation is neuroprotective against retinal neurodegeneration.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Animals, Newborn; Apoptosis; Cell Survival; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluorescent Antibody Technique, Indirect; In Situ Nick-End Labeling; Intravitreal Injections; Male; N-Methylaspartate; Neuroprotection; Optic Nerve Injuries; Organ Culture Techniques; Rats; Rats, Wistar; Receptor, Adenosine A3; Retina; Retinal Degeneration; Retinal Neurons | 2015 |
Role of A3 adenosine receptor in diabetic neuropathy.
Topics: Action Potentials; Adenosine; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Disease Models, Animal; Eating; Hyperalgesia; Male; Mice; Muscle, Skeletal; Neural Conduction; NF-kappa B; Pain Threshold; Receptor, Adenosine A3; Sciatic Nerve; Spinal Cord; Streptozocin | 2016 |
Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Blood Pressure; Disease Models, Animal; In Vitro Techniques; Lung; Lung Compliance; Lung Diseases; Perfusion; Peroxidase; Piperidines; Protective Agents; Pulmonary Artery; Pulmonary Edema; Rabbits; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A3; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2010 |
A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.
Topics: Adenosine; Anesthesia; Animals; Cardiotonic Agents; Coronary Circulation; Disease Models, Animal; Dogs; Iodine Radioisotopes; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptor, Adenosine A3; Receptors, Purinergic P1 | 2003 |
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis.
Topics: Adenosine; Animals; Chemokine CCL4; Chemokine CXCL2; Chemokines; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Interleukin-1; Interleukin-12; Interleukin-6; Macrophage Inflammatory Proteins; Male; Malondialdehyde; Mice; Mice, Inbred BALB C; Mice, Knockout; Peroxidase; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Rectal Diseases; Weight Loss | 2003 |
A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Endotoxemia; Escherichia coli; Escherichia coli Infections; Female; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Purines; Receptors, Adenosine A2; Sepsis; Survival Analysis | 2004 |
Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis.
Topics: Adenosine; Animals; Apoptosis; Cats; Disease Models, Animal; In Situ Nick-End Labeling; Lung; Lung Injury; Receptor, Adenosine A3; Reperfusion Injury | 2004 |
ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Colitis; Disease Models, Animal; Free Radicals; Gene Expression Regulation; Glutathione Peroxidase; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Trinitrobenzenesulfonic Acid | 2006 |
Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart.
Topics: Adenosine; Animals; Disease Models, Animal; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Phenylisopropyladenosine; Rabbits; Receptors, Purinergic; Stimulation, Chemical | 1997 |
Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists.
Topics: Adenosine; Animals; Arthritis; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Collagen; Cytokines; Disease Models, Animal; Gene Expression; Macrophage Activation; Macrophage Inflammatory Proteins; Macrophages; Mice; Mice, Inbred DBA; Purinergic P1 Receptor Agonists; RNA, Messenger | 1998 |